Cell Culture

Will Delivery Science Decide Which Biologics Reach Patients?
Biotech & Bioprocessing Will Delivery Science Decide Which Biologics Reach Patients?

The drumbeat behind next-generation biologics has been unmistakable, yet the loudest voices in today’s pipelines keep returning to a sobering reality: delivery is not polish at the finish line, it is the race itself, where fragile molecules, strict dosing windows, and hard-to-reach tissues force

Building Immune-Protected Beta Cells to Cure Type 1 Diabetes
Tech & Innovation Building Immune-Protected Beta Cells to Cure Type 1 Diabetes

Every three minutes somewhere in the world, a person with type 1 diabetes calculates a dose of insulin and still lives with the nagging reality that even perfect math will not reproduce the split-second precision of native β-cells. Clinicians point to the autoimmune destruction that erased those

Dampening pDCs Restores T Cells and Shrinks HIV Reservoirs
Biotech & Bioprocessing Dampening pDCs Restores T Cells and Shrinks HIV Reservoirs

Chronic HIV infection, even under suppressive antiretroviral therapy, can trap the immune system in a state of simmering alarm that never fully resolves and quietly erodes the fitness of the very T cells needed for durable control of the virus. That conundrum has intensified attention on the small

Can Host Cell Control Points Stop Multiple Viruses?
Tech & Innovation Can Host Cell Control Points Stop Multiple Viruses?

Diving into the world of virology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development. With a deep understanding of technology and innovation in the industry, Ivan has been at the forefront of groundbreaking discoveries.

Can FDA's CNPV Program Balance Speed and Safety Risks?
Biotech & Bioprocessing Can FDA's CNPV Program Balance Speed and Safety Risks?

The pharmaceutical landscape is on the brink of a seismic shift with the introduction of the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, a bold initiative designed to cut the review timeline for drug and biological product applications from the standard 10-12 months down to

Cell-Free DNA: Revolutionizing Advanced Therapy Development
Biotech & Bioprocessing Cell-Free DNA: Revolutionizing Advanced Therapy Development

In the rapidly evolving field of biopharmaceuticals, a groundbreaking shift is capturing the attention of industry leaders and innovators alike, promising to redefine the development of advanced therapies with remarkable potential. This transformation centers on the adoption of cell-free DNA as a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later